BCM
CRVS icon

Bayesian Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Bayesian Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,500
Closed -$70K – 586
2025
Q2 		$70K Buy
+17,500
New +$63.7K 0.01% 499

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bayesian Capital Management's CRVS Position: Q3 2025 in Review

Bayesian Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q3 2025, closing a stake of 17,500 shares — an estimated $70K sold.

Bayesian Capital Management first reported a position in CRVS in Q2 2025 and held it in 1 quarter. The position peaked at $70K in Q2 2025. 102 funds tracked by Wall St. Rank hold CRVS as of Q3 2025.

  • Bayesian Capital Management reported no remaining Corvus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 17,500 Corvus Pharmaceuticals shares in Q3 2025, an estimated $70K.
  • Bayesian Capital Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Bayesian Capital Management's Corvus Pharmaceuticals position peaked at $70K in Q2 2025.
  • 102 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.